William Blair reiterated their buy rating on shares of Pandora Media Inc (NYSE:P) in a research report sent to investors on Tuesday morning. On Friday shares of Pandora Media Inc (NYSE:P) closed at $16.44. Company’s sales growth for last 5 years was 75.60% and EPS growth for next 5 years is recorded as 43.03%.
Galena Biopharma Inc. (NASDAQ:GALE) announced the pricing of an underwritten public offering of 24,358,974 units at a public offering price of $1.56 per unit, for total gross proceeds of $38.0 million. Each unit consists of one share of common stock and a warrant to purchase 0.5 of a share of common stock at an exercise price of $2.08 per share. Galena Biopharma, Inc. (NASDAQ:GALE) in last trading activity moved down -17.92% to close at $1.42. Company weekly performance is -24.47% while its quarterly performance stands at -13.94%. Galena Biopharma, Inc. (NASDAQ:GALE) is -60.34% away from its 52 week high.
SunEdison Inc. (NYSE:SUNE) has recently secured an agreement for developing 9.6 MW utility scale solar power plant in Japan. With this project, SunEdison will be the first US company in Japan to secure the construction of a solar plant namely, the Tarumizu project. On Friday shares of SunEdison, Inc. (NYSE:SUNE) closed at $23.66. Company’s sales growth for last 5 years was 16.40% and EPS growth for next 5 years is recorded as 1.58%.
On March 9, Resolute Energy Corporation (NYSE:REN) reported that its loss narrow to $21.85 million, or $0.30 a share for the quarter ended Dec. 31, 2014. In the previous year period, the company reported a loss of $113.81 million, or $1.67 a share. Resolute Energy Corporation (NYSE:REN) has 5.60% insider ownership while its institutional ownership stands at 83.70%. In last trading activity company’s stock closed at $0.62.
Fate Therapeutics Inc. (NASDAQ:FATE) on Thursday reported a loss of $6.2 million in its fourth quarter. For the year, the company reported that its loss widened to $25.9 million, or $1.27 per share. On last trading day Fate Therapeutics, Inc. (NASDAQ:FATE) moved down -0.59% to close at $5.05. Its volatility for the week is 6.24% while volatility for the month is 6.95%. Fate Therapeutics, Inc. (NASDAQ:FATE) monthly performance is 1.00%.